Effect of Androgen receptors in Triple-Negative Breast Cancer Given Neoadjuvant Therapy: A Systematic Review and Meta-Analysis
Ottofianus Alvedo Hewick Kalangi, Tioky Sutjonong, Erica A Indrawan, Hayyan Ageng Pratama, Yohana Azhar, Asdi Wihandono · 2024
Read Effect of Androgen receptors in Triple-Negative Breast Cancer Given Neoadjuvant Therapy: A Systematic Review and Meta-Analysis by Ottofianus Alvedo Hewick Kalangi, Tioky Sutjonong, Erica A Indrawan, Hayyan Ageng Pratama, Yohana Azhar, Asdi Wihandono (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12008318.txt.
Description
Ottofianus Kalangi and co-authors pool prior studies on whether the androgen receptor changes how triple-negative breast cancer answers early chemotherapy, in a 2024 review. This cancer type lacks the three usual drug targets, leaving few options, and the androgen receptor is one candidate target. Fifteen cohort studies covering 2,713 patients were combined.
Patients whose tumors carried the receptor responded less well to chemotherapy given before surgery than those without it. Survival leaned the other way: receptor-positive patients showed slightly better three-year disease-free and overall survival, though neither gap was statistically firm. The authors conclude the receptor's value as a guide is still unsettled and needs sharper study.
Catalog record
| CREATOR | Ottofianus Alvedo Hewick Kalangi, Tioky Sutjonong, Erica A Indrawan, Hayyan Ageng Pratama, Yohana Azhar, Asdi Wihandono |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 19 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |